Glenmark receives ANDA approval for Bisoprolol Fumarate and Hydrochlorothiazide Tablets USP

Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Bisoprolol Fumarate and Hydrochlorothiazide Tablets USP, 2.5 mg/6.25 mg, 5 mg/6.25 mg, and 10 mg/6.25 mg, the generic version of Ziac® Tablets, 2.5 mg/6.25 mg, 5 mg/6.25 mg, and 10 mg/6.25 mg, of Teva Branded Pharmaceutical Products R&D, Inc.

According to IQVIA™ sales data for the 12 month period ending November 2021, the Ziac® Tablets, 2.5 mg/6.25 mg, 5 mg/6.25 mg, and 10 mg/6.25 mg market achieved annual sales of approximately $30.3 million*.

Glenmark's current portfolio consists of 172 products authorized for distribution in the U.S. marketplace and 46 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 485.65 as compared to the previous close of Rs. 471.70. The total number of shares traded during the day was 52099 in over 1908 trades.

The stock hit an intraday high of Rs. 487.45 and intraday low of 465.85. The net turnover during the day was Rs. 24971241.00.

Source : Equity Bulls

Keywords

GlenmarkPharmaceuticals INE935A01035 ANDAApproval USFDA BisoprololFumarate HydrochlorothiazideTablets